EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome

Katta Sai, Amos Lal, Jhansi Lakshmi Maradana, Pruthvi Raj Velamala, Trivedi Nitin

Endocrinology, Diabetes & Metabolism Case Reports · 12.11.2019 · 2019

DOI: 10.1530/edm-19-0064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 12.11.2019. Verfasst von Katta Sai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Saint Vincent Hospital at Worcester Medical Center, Worcester, Massachusetts, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mifepristone is a promising option for the management of hypercortisolism associated with hyperglycemia. However, its use may result in serious electrolyte imbalances, especially during dose escalation. In our patient with adrenocorticotropic hormone-independent macro-nodular adrenal hyperplasia, unilateral adrenalectomy resulted in biochemical and clinical improvement, but subclinical hypercortisolism persisted following adrenalectomy. She was started on mifepristone. Unfortunately, she missed her follow-up appointments following dosage escalation and required hospitalization at an intensive care level for severe refractory hypokalemia. Learning points: Mifepristone, a potent antagonist of glucocorticoid receptors, has a high risk of adrenal insufficiency, despite high cortisol levels. Mifepristone is associated with hypokalemia due to spill-over effect of cortisol on unopposed mineralocorticoid receptors. Given the lack of a biochemical parameter to assess improvement, the dosing of mifepristone is based on clinical progress. Patients on mifepristone require anticipation of toxicity, especially when the dose is escalated. The half-life of mifepristone is 85 h, requiring prolonged monitoring for toxicity, even after the medication is held.

Schlagwörter

Stichwörter der Autor:innen

2019ACTHAdrenalAdrenal venous samplingAdrenalectomyAdrenocortical adenomaAdultBrain natriuretic peptideCT scanCortisolCortisol (9am)Creatine kinaseCushing's syndromeDHEADHEA Sulphate

Autor:innen und Institutionen

  • Department of Internal Medicine, Saint Vincent Hospital at Worcester Medical Center, Worcester, Massachusetts, USA.
  • Department of Endocrinology, Diabetes, and Metabolism, Saint Vincent Hospital at Worcester Medical Center, Worcester, Massachusetts, USA.

Zitieren

APA

Sai, K., Lal, A., Lakshmi Maradana, J., Velamala, P. R., & Nitin, T. (2019). Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome. Endocrinology, Diabetes & Metabolism Case Reports, 2019. https://doi.org/10.1530/edm-19-0064

Vancouver

Sai K, Lal A, Lakshmi Maradana J, Velamala PR, Nitin T. Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome. Endocrinology, Diabetes & Metabolism Case Reports. 2019;2019. doi:10.1530/edm-19-0064

BibTeX
@article{Sai2019,
  author = {Sai, Katta and Lal, Amos and Lakshmi Maradana, Jhansi and Velamala, Pruthvi Raj and Nitin, Trivedi},
  title = {Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2019},
  volume = {2019},
  doi = {10.1530/edm-19-0064}
}
Kostenlos starten →